Jubilant Life falls 6% as USFDA recommends action on failing inspection

The stock dipped 6% to Rs 742 on the BSE after the US health regulator recommended a regulatory or administrative action after the inspection of the drug firm's Roorkee manufacturing facility.

from Latest News https://ift.tt/2Edo3rc
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share